rapa-501-allo
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 30, 2020 (NCT04482699)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
immunity, passive - sars-cov-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04482699 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2020 | Hackensack University Medical Center, Rapa Therapeutics LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hackensack University Medical Center | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Rapa Therapeutics LLC | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1